Quince Therapeutics, Inc. Operating Income Loss

Quick Answer

Quince Therapeutics, Inc. reported Operating Income Loss of -$57.29 million for the year ending 2024.

  • Quince Therapeutics, Inc. showed a decrease of -65.5% in Operating Income Loss from 2023 to 2024.
  • This data is from Quince Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
  • XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2018 to 2024), Quince Therapeutics, Inc.'s Operating Income Loss has declined by 372.7%.
  • Historical annual values: Fiscal year 2024: -$57.29 million | Fiscal year 2023: -$34.62 million | Fiscal year 2022: -$52.02 million | Fiscal year 2021: -$90.32 million | Fiscal year 2020: -$78.89 million | Fiscal year 2019: -$39.17 million | Fiscal year 2018: -$12.12 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: